Hyperthermia exhibits anti-vascular activity in the s.c. BT4An rat glioma: Lack of interaction with the angiogenesis inhibitor batimastat

International Journal of Hyperthermia

Volumn 18, Issue 2, 2002, Pages 141-152

  Eikesdal, Hans P ^a   Bjorkhaug, S T ^a   Dahl, O ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Anti vascular therapy; Batimastat; Hyperthermia; Tumour blood flow

Indexed keywords

ANGIOGENESIS INHIBITOR; BATIMASTAT; RUBIDIUM CHLORIDE RB 86; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL INJURY; CANCER INHIBITION; COMPARATIVE STUDY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG SCREENING; FEMALE; GLIOMA; HEAT TREATMENT; HYPERTHERMIC THERAPY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; RAT; SUBCUTANEOUS TISSUE TUMOR; THERMAL EXPOSURE; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; BRAIN NEOPLASMS; FEMALE; GLIOMA; HYPERTHERMIA, INDUCED; MALE; PHENYLALANINE; RATS; THIOPHENES;

EID: 0036119967     PISSN: 02656736     EISSN: None     Source Type: Journal    
DOI: 10.1080/02656730110090712     Document Type: Article

References (54)

1. The onset and extent of genomic instability in sporadic colorectal tumor progression
2. Acquired drug resistance driven by tumor cell genetic instability: Circumvention by direct-acting anti-angiogenic vascular targeting agents
3. The hallmarks of cancer
4. Initial stages of tumor cell-induced angiogenesis: Evaluation via skin window chambers in rodent models
5. Angiostatin induces and sustains dormancy of human primary tumors in mice
6. Anti-angiogenic agents. Clinical trial design and therapies in development
7. Thermal sensitivity of endothelial cells
8. Hyperthermia inhibits angiogenesis
9. Effect of local hyperthermia on blood flow and microenvironment: A review
10. Tumour vasculature - A potential therapeutic target
11. Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia
12. Matrix metalloproteinase inhibitors: A new class of anticancer agent
13. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases
14. Matrix metalloproteinase inhibition: A review of anti-tumour activity
15. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer
16. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94), 2.5mg/ml, 30 mg/kg i.p.
17. Combretastatin A-4 and hyperthermia; A potent combination for the treatment of solid tumors
18. The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma
19. The measurement of blood perfusion in experimental tumors by uptake of 86Rb
20. Vascular attack as a therapeutic strategy for cancer
21. Antiangiogenic chemotherapeutic agents: Characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models
22. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
23. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
24. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma
25. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
26. Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor
27. Endothelial proliferation in tumours and normal tissues: Continous labelling studies
28. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
29. Reduced thermal sensitivity of the vasculature in a slowly growing tumour
30. Blood flow in human tumors during hyperthermia therapy: Demonstration of vasoregulation and an applicable physiological model
31. Blood flow in human tumors during local hyperthermia
32. Relationship between heat-induced vascular damage and thermosensitivity in four mouse tumors
33. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
34. Disparate responses of tumour vessels to angiotensin II: Tumours volume-dependent effects on perfusion and oxygenation
35. Site dependent response of tumours to combined heat and radiation
36. Induction of thermoresistance in tumour blood vessels
37. Effects of hyperthermia on bioenergetic status and phosphorus T1S in human melanoma xenografts monitored by 31P-MRS
38. Vascular occlusion and tumour cell death
39. Fractionated hyperthermia in vivo: Thermotolerance, sensitivity to BCNU and thermochemosensitivity in the BT4An rat glioma
40. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel
41. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: Clinical implications
42. TNP-470/minocycline/cytotoxic therapy: A systems approach to cancer therapy
43. Combined effects of angiostatin and ionizing radiation in antitumour therapy
44. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation
45. Tumor angiogenesis: Past, present and the near future
46. The influence of tumor blood flow and microenvironmental factors on the efficacy of radiation, drugs and localized hyperthermia
47. Tumor cell sensitivity to hyperthermia as a function of extracellular and intracellular pH
48. Enhancement effect of an anti-angiogenic agent, TNP-470, on hyperthermia-induced growth suppression of human esophageal and gastric cancers transplantable to nude mice
49. Induction of vascular endothelial growth factor (VEGF) by hyperthermia and/or an angiogenesis inhibitor
50. Elevated levels of Mr 92,000 type IV collagenase in human brain tumors
51. Transmembrane neural cell-adhesion molecule (NCAM), but not glycosyl-phosphatidylinositol-anchored NCAM, down-regulates secretion of matrix metalloproteinases
52. Tumor angiogenesis - A new therapeutic target in gliomas
53. Contribution of metalloproteinase-dependent and urokinase-dependent proteolytic pathways in lung cancer-mediated dissolution of extracellular matrix (ECM)